Axogen Inc. has reported its financial results for the second quarter of 2025, showcasing a positive performance with a notable increase in revenue. The company achieved a revenue of $56.7 million, representing an 18.3% increase compared to $47.9 million in the same quarter of the previous year. Net income turned positive at $0.6 million, compared to a loss of $1.9 million in Q2 2024. Additionally, the adjusted net income improved significantly to $5.7 million from $2.0 million in the prior year. The earnings per share $(EPS)$ were $0.01, a reversal from a loss of $0.04 per share in the previous year, with the adjusted EPS rising to $0.12 from $0.05. The company's gross margin slightly increased to 74.2% from 73.8% in the prior year, reflecting a 0.4% improvement. Operating cash flow also saw an increase, with operational cash standing at $35.9 million as of June 30, 2025, up from $28.1 million on March 31, 2025. Looking ahead, Axogen Inc. has raised its guidance for the full-year 2025, anticipating a revenue growth of at least 17%, equating to $219 million, and maintaining a gross margin between 73% and 75%. The company also expects to achieve a net cash flow positive status. Additionally, a significant business update includes the Biologics License Application for Avance Nerve Graft®, with anticipation of FDA approval in the United States by September 2025.